Navigation Links
Barr Reports Second Quarter 2008 GAAP Earnings of $0.52 Per Share; Adjusted Earnings of $0.64 Per Share
Date:8/7/2008

g sales growth in this product in the second half of 2008 while we remain the only generic available on the U.S. market. Our SEASONIQUE(R) extended-cycle oral contraceptive and the PARAGARD(R) IUC were the principal drivers in higher proprietary product sales year-over-year."

"The strength of our generic and proprietary product portfolios, our commercial strength in important global markets, and our focus on delivering sound results are among the benefits that make the proposed acquisition of Barr by Teva, announced on July 18th, so attractive. Management is committed to continuing to deliver strong performance as the acquisition process progresses, to ensure that at the close of the transaction, the capabilities of Barr will significantly complement Teva's existing business," Downey continued.

Revenues

Generic Product Sales

The Company's generic product sales were $557 million for the second quarter of 2008, compared to $484 million in the prior year period. For the first six months of 2008, generic product sales were $1.0 billion, compared to $956 million for the prior year period. A discussion of the Company's generic product sales for the second quarter of 2008 compared to the prior year period is presented below.

North American

Sales of North American generic products totaled $340 million for the

second quarter of 2008, compared to $296 million in the prior year period.

The increase in sales is primarily related to higher sales of generic oral

contraceptives.

Sales of generic oral contraceptives increased 34% to $155 million in the

second quarter of 2008, up from $116 million in the prior year period.

The increase primarily reflects sales of Ocella(TM), the Company's generic

Yasmin(R) oral contraceptive product that was launched at the end of the

second quarter of 2008, which more than offset lower volume and pricing on

several other oral contraceptive
'/>"/>

SOURCE Barr Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results
2. Caliper Life Sciences Reports Second Quarter 2008 Results
3. Watson Pharmaceuticals Reports Second Quarter 2008 Results
4. EntreMed Reports Second Quarter 2008 Financial Results
5. Transgenomic Reports Second Quarter 2008 Results
6. Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results
7. Bionovo Reports Second Quarter 2008 Financial Results
8. AtriCure Reports Record Second Quarter 2008 Financial Results
9. AMICAS Reports Financial Results for the Second Quarter Ended June 30, 2008
10. eResearchTechnology Reports Second Quarter 2008 Results
11. SuperGen Reports 2008 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/19/2014)... (PRWEB) October 19, 2014 The Asian ... in Asian with analysis and forecast of revenue. The ... grow to around $463.9 million by 2018, at a ... Browse through the TOC of the Asian Automatic patient ... analysis provided. This also provides a glimpse of the ...
(Date:10/19/2014)... October 19, 2014 The report "Chocolate, ... Share, Trade, Prices, Geography Trend and Forecast (2011 - ... category, and geography and studies the major market drivers, ... America, Europe, and Asia. , The global chocolate market ... $98.3 billion in 2016 at an estimated CAGR of ...
(Date:10/19/2014)... October 19, 2014 The report ... & Homeland Security), Technology, Payload, Type & by ... segments the global unmanned ground vehicle market into ... forecasting of market sizes. The report also identifies ... opportunities impacting it along with the adoption trends. ...
(Date:10/18/2014)... The “Human Insulin Market- by Product Type, [Human ... Insulin (Rapid Acting, Long Acting, Premixed)], by Brand ... Forecast to 2018” provides a detailed overview of ... trends, and strategies impacting the global human insulin ... the revenue and share analysis. , The global ...
Breaking Biology Technology:The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 2The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 3Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 2Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 3Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 4Unmanned Ground Vehicle (UGV) Market Estimated to Reach $8.26 Billion by 2020 - New Research Report by MarketsandMarkets 2Unmanned Ground Vehicle (UGV) Market Estimated to Reach $8.26 Billion by 2020 - New Research Report by MarketsandMarkets 3Unmanned Ground Vehicle (UGV) Market Estimated to Reach $8.26 Billion by 2020 - New Research Report by MarketsandMarkets 4Unmanned Ground Vehicle (UGV) Market Estimated to Reach $8.26 Billion by 2020 - New Research Report by MarketsandMarkets 5Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 2Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 3Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 4Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 5
... , ROCKVILLE, Md. , Aug. 6 ... today the appointment of Richard Douglas , Ph.D. to ... President, Corporate Development at Genzyme Corp.  As a leader of ... numerous acquisitions, licenses, joint ventures and strategic alliances as well ...
... Arizona State University researchers will get support from the ... next generations of lasers and infrared photodetectors. ... for an array of defense and commercial applications. ... Office grant through the defense department,s Multidisciplinary University Research ...
... Vicept Therapeutics, Inc., a privately held specialty biopharmaceutical company, announced ... the Company,s lead product V-101, a topical cream under investigation for ... , , ... crossover clinical trial of 22 patients with rosacea was designed to ...
Cached Biology Technology:NOVAVAX Elects Richard H. Douglas to its Board of Directors 2NOVAVAX Elects Richard H. Douglas to its Board of Directors 3Looking to leap forward on laser and photodetector technologies 2Vicept Therapeutics Announces Positive Clinical Study Results of V-101 for the Treatment of the Erythema of Rosacea 2Vicept Therapeutics Announces Positive Clinical Study Results of V-101 for the Treatment of the Erythema of Rosacea 3
(Date:10/15/2014)... , Oct. 15, 2014 Sandata ... for home and community-based care, today announced it ... implementing Sandata,s Santrax® Electronic Visit Verification™ Solution (EVV™) ... is a home health company founded in 1996 ... . The study details ...
(Date:10/15/2014)... of Life, is a non-traditional biophysics textbook and it ... is a journey of discovery into biological systems and ... biological regulation. It is about how our genes make ... the billions of cells in an organism. It quantifies ... principles, which can be found on both large and ...
(Date:10/15/2014)... virus is spreading rapidly and to an unexpected extent. ... the past and the virus shows a new disease ... before. For this reason, the German National Academy of ... and Engineering, and the Union of the German Academies ... the Ebola epidemic today. , In the statement the ...
Breaking Biology News(10 mins):Sandata Announces Case Study with Quality Care Services, Inc. 2New book about life as seen from physics 2Academies call for consequences from the Ebola virus epidemic 2Academies call for consequences from the Ebola virus epidemic 3Academies call for consequences from the Ebola virus epidemic 4Academies call for consequences from the Ebola virus epidemic 5
... 1, 2011 A pathway whereby bacteria communicate with ... Hebrew University of Jerusalem. The discovery has important implications ... bacteria in the body. Bacteria are known to ... of extracellular signalling molecules, said Prof. Sigal Ben-Yehuda of ...
... is known to have cancer-protective properties, and shift work ... production. Shift work has been thought to have important ... increased risk of several cancers including breast, endometrial, prostate, ... study, researchers at Brigham and Women,s Hospital (BWH) found ...
... SEATTLE Twelve graduate students from institutes throughout ... Harold M. Weintraub Graduate Student Award sponsored by the ... Nominations were solicited internationally; the winners were selected on ... their work. , The recipients, all advanced students at ...
Cached Biology News:Shift work may be associated with decreased risk of skin cancer 22011 Harold M. Weintraub Graduate Student Award recipients announced 22011 Harold M. Weintraub Graduate Student Award recipients announced 3
The E. coli Expression System with Gateway Technology is designed to create E. coli expression clones containing the T7 promoter. The expression clones are ready for transformation and expression in ...
...
For use with SSP products or any application requiring agarose gel separation • Multiple formats available to meet various throughput needs • Includes replacement parts for each un...
...
Biology Products: